Wang Jun, Cao Hui, Wang Hongjie, Yin Guoxiao, Du Jiao, Xia Fei, Lu Jingli, Xiang Ming
Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Pharmacology, College of Medicine, Wuhan University of Science and Technology, Wuhan, China.
Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Toxicol Appl Pharmacol. 2015 Jun 15;285(3):149-58. doi: 10.1016/j.taap.2015.04.006. Epub 2015 Apr 17.
Toll-like receptor 4 (TLR4) activation has been proposed to be important for islet cell inflammation and eventually β cell loss in the course of type 1 diabetes (T1D) development. However, according to the "hygiene hypothesis", bacterial endotoxin lipopolysaccharide (LPS), an agonist on TLR4, inhibits T1D progression. Here we investigated possible mechanisms for the protective effect of LPS on T1D development in non-obese diabetic (NOD) mice. We found that LPS administration to NOD mice during the prediabetic state neither prevented nor reversed insulitis, but delayed the onset and decreased the incidence of diabetes, and that a multiple-injection protocol is more effective than a single LPS intervention. Further, LPS administration suppressed spleen T lymphocyte proliferation, increased the generation of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs), reduced the synthesis of strong Th1 proinflammatory cytokines, and downregulated TLR4 and its downstream MyD88-dependent signaling pathway. Most importantly, multiple injections of LPS induced a potential tolerogenic dendritic cell (DC) subset with low TLR4 expression without influencing the DC phenotype. Explanting DCs from repeated LPS-treated NOD mice into NOD/SCID diabetic mice conferred sustained protective effects against the progression of diabetes in the recipients. Overall, these results suggest that multiple mechanisms are involved in the protective effects of LPS against the development of diabetes in NOD diabetic mice. These include Treg induction, down-regulation of TLR4 and its downstream MyD88-dependent signaling pathway, and the emergence of a potential tolerogenic DC subset.
Toll样受体4(TLR4)的激活被认为在1型糖尿病(T1D)发展过程中对胰岛细胞炎症以及最终的β细胞丢失起重要作用。然而,根据“卫生假说”,细菌内毒素脂多糖(LPS)作为TLR4的激动剂,可抑制T1D的进展。在此,我们研究了LPS对非肥胖糖尿病(NOD)小鼠T1D发展产生保护作用的可能机制。我们发现,在糖尿病前期状态下给NOD小鼠注射LPS既不能预防也不能逆转胰岛炎,但能延迟糖尿病的发病并降低其发病率,且多次注射方案比单次LPS干预更有效。此外,注射LPS可抑制脾脏T淋巴细胞增殖,增加CD4(+)CD25(+)Foxp3(+)调节性T细胞(Tregs)的生成,减少强效Th1促炎细胞因子的合成,并下调TLR4及其下游MyD88依赖性信号通路。最重要的是,多次注射LPS可诱导出一种TLR4表达较低的潜在致耐受性树突状细胞(DC)亚群,而不影响DC的表型。将反复接受LPS处理的NOD小鼠的DC移植到NOD/SCID糖尿病小鼠体内,可对受体小鼠糖尿病的进展产生持续的保护作用。总体而言,这些结果表明,LPS对NOD糖尿病小鼠糖尿病发展的保护作用涉及多种机制。这些机制包括诱导Tregs、下调TLR4及其下游MyD88依赖性信号通路,以及出现潜在的致耐受性DC亚群。